Challenging myelofibrosis cases
Dr Jen O’Sullivan, University of Oxford & GSTT

When to take an MF patient to BMT
Dr Juan Carlos Hernández-Boluda, Hospital Clínico of Valencia

Eosinophilia with ASXL mutation – a case
Dr Rebecca Frewin, Gloucestershire Hospitals

Indolent mastocytosis – case-based discussion
Dr Deepti Radia, Guy’s and St Thomas’ Hospital, London

Immunotherapy for MPN options now and in pipeline
Professor Beth Psaila, University of Oxford

Update on prognostic models in MPN focus on MF
Professor Francesco Passamonti, University of Milan

Modern management of myelofibrosis
Professor Serge Verstovsek, Chief Medical Officer, Kartos Therapeutics, California

A new era of therapy for PV
Professor Mary Frances McMullin, Queen’s University Belfast

Technological advances in assessment of MPN
Dr Patrick Harrington, Guy’s and St Thomas’ Hospital, London

Can we move to molecular monitoring in MPN?
Professor Adam Mead, University of Oxford

Blast phase MPN and relevant AML management
Professor Steve Knapper, University Hospital of Wales, Cardiff

New treatments for MPN
Dr Claire Harrision, Guy’s and St Thomas’ Hospital, London

When does a patient with a high Hb need to be managed by a haematologist?
Dr Claire Harrision, Guy’s and St Thomas’ Hospital, London

Triple negative thrombocytosis
Dr Anna Godfrey, Addenbrooke’s Hospital, Cambridge

Important updates for the MPN clinician: cardiology
Dr Alex Lyon, Royal Brompton Hospital

Important updates for the MPN clinician: endocrine
Dr Yaasir Mamoojee, Newcastle Upon Tyne Hospitals 

Registration is free of charge

The programme for the second CLL Study Day for Nurses will provide nurses and allied health professionals working in this disease area with a useful opportunity to share latest data and best practice, keep up-to-date with changes in practice and lots more.

Haematological considerations for patients with liver disease
Dr Jecko Thachil, Manchester Royal Infirmary

Acquired VWD: Clinical presentations
Dr Gary Benson, Northern Ireland Haemophilia Centre

BSH VWD Guideline update – the way forwards
Dr Will Lester, University Hospital of Birmingham, Queen Elizabeth and Birmingham Women’s Hospital

ADAMTS13 Testing: Issues, stories and solutions
Dr Steve Kitchen, Sheffield Haemophilia and Thrombosis Centre

An educational resource from Grifols

This national forum is intended to provide a resource for UK haematologists and research nurses treating patients with AML. Working closely with Charles Craddock, Steve Knapper, Mike Dennis, Mhairi Copland and Victoria Potter it has been possible to create a varied and compelling programme covering many of the recent breakthroughs which are of such importance to our patients.

Advance care planning
Dr Richard Towers, King’s College Hospital, London

Behavioural science for well-being and recovery
Ross McIntosh, Organisational Psychologist and host of the People Soup Podcast

Lung GVHD – the importance of early detection
Dr Saskia Bos, Newcastle upon Tyne Hospitals

CAR-T service development. Nursing element – ICANS and CRS
Bethany Colton, Sheffield Teaching Hospitals

Professional nurse advocacy in BMT and Aspirant Cancer Career and Education Development (ACCEND)
Sara Main, University Hospital Southampton

EBMT Dietetic Sub-Group: Nutritional support during CAR-T
Natasha Jones (Cambridge) and Nicola Scott (Leeds)

EBMT AHP Sub-Group: Rehabilitation within stem cell transplantation
Orla McCourt, University College London

Registration is free of charge

Combining clinical trial evidence and real-world patient management cases, this session will cover where BRUKINSA® could be a treatment option for patients with CLL
Led by Dr Dima El-Sharkawi, The Royal Marsden NHS Foundation Trust
Panel: Dr Piers Patten, Dr Renata Walewska, Dr Talha Munir

An educational resource from BeiGene
Registration is free of charge

Please click here to access the Brukinsa▼ (zanubrutinib) prescribing and adverse event reporting information. Adverse events should be reported via the MHRA Yellow Card Scheme found at www.mhra.gov.uk/yellowcard and also to BeiGene at adverse_events@beigene.com

Case-based panel discussion
Led by Professor George Follows, Addenbrooke’s Hospital
Panel:    Dr Pam McKay, Beatson West of Scotland Cancer Centre
Dr Sarah Lawless, Belfast City Hospital
Dr Vishal Jayakar, Kingston Hospital
Dr Toby Eyre, Oxford University Hospitals

What’s new in CLL
Dr Toby Eyre, Oxford University Hospitals

An educational resource from BeiGene

Registration is free of charge

Please click here to access the Brukinsa▼ (zanubrutinib) prescribing and adverse event reporting information. Adverse events should be reported via the MHRA Yellow Card Scheme found at www.mhra.gov.uk/yellowcard and also to BeiGene at adverse_events@beigene.com

Advances in the application of radiotherapy
Professor Tim Illidge, The Christie Hospital

Lymphoma biology
Dr Cathy Burton, HMDS, Leeds

25 years of antibody treatment for lymphoma
Professor Peter Johnson, University Hospital Southampton

CAR T cell update
Dr Andrea Kuhnl, King’s College Hospital

Aggressive lymphoma
Professor Chris Fox, Nottingham University Hospitals

Follicular lymphoma
Dr Will Townsend, UCLH

Mantle cell lymphoma
Dr David Lewis, Plymouth University Hospitals

CLL
Dr Piers Patten, King’s College London

T-cell lymphoma
Dr Kate Cwynarski, UCLH

CNS lymphoma
Dr Wendy Osborne, NCCC, Newcastle 

Registration is free of charge

Additional lecture: Pregnancy in ITP
From Professor Jim Bussel, Weill Cornell Medical College, New York

Update on the pathobiology of ITP
Professor John Semple, Lund University, Sweden

Is B cell depletion safe?
Professor Marc Michel, Henri Mondor University Hospital, Paris

How should we use TPO-RA beyond ITP?
Professor Marisa Lozano, University of Murcia, Spain

Older drugs for new regimes
Dr Charlotte Bradbury, University Hospitals Bristol

SYK inhibitor: How to use fostamatinib – the French experience
Dr Guillaume Moulis, Toulouse University Hospital

Debate: TPOs should be used in second line?
For: Dr Drew Provan, Barts & The London School of Medicine, London
Against: Professor Marc Michel, Henri Mondor University Hospital, Paris

Thrombosis in ITP
Professor Waleed Ghanima, Østfold Hospital, Oslo

FcRn inhibition
Professor Francesco Zaja, University Hospital Trieste, Italy

BTK inhibition: The latest data
Professor David Kuter, Massachusetts General Hospital, Boston

Case Presentation: Complications ITP or treatment?
Dr Alice Hart, Imperial College London

What’s on the horizon?
Professor David Kuter, Massachusetts General Hospital, Boston

Registration is free of charge

Updates on GVHD
Professor Mohamad Mohty, Saint-Antoine Hospital, Paris

Updates on lymphoma
Dr Anna Sureda, Catalan Institute of Oncology, Barcelona

BiTEs and other immunotherapies versus CAR T in myeloma
Dr Emma Searle, The Christie Hospital, Manchester

CAR-T therapy for AML: is it realistic?
Dr Sara Ghorashian, GOSH

Advances on prevention and treatment of graft-versus-host-disease
Dr Francesca Kinsella, University of Birmingham

The future of conditioning regimens
Dr Muhammad Saif, Clatterbridge Cancer Centre, Liverpool

AML chemo to transplant
Dr Pramila Krishnamurthy, King’s College Hospital, London

Registration is free of charge

Adult ALL risk score
Professor Anthony Moorman, Newcastle University

Key challenges, including monitoring of BCR-ABL+ disease
Dr Bela Wrench, Barts Cancer Institute

Management of Philadelphia +ve ALL
Dr Tobias Menne, Newcastle upon Tyne Hospitals

T-cell ALL challenges
Dr Clare Rowntree, University Hospital of Wales

Treatment of relapsed B-cell ALL
Dr Sridhar Chaganti, University Hospitals Birmingham

Myeloma frontline
Professor Graham Jackson, NCCC, Newcastle

Relapsed myeloma
Dr Charlotte Pawlyn, Royal Marsden Hospital

Myeloma horizon scanning
Dr Rakesh Popat, UCLH

Lymphoma biology
Dr Jessica Okosun, Barts Cancer Institute

CLL
Dr Piers Patten, King’s College London

MCL and low grade lymphoma
Dr Toby Eyre, Oxford University Hospitals

High grade and CNS lymphoma
Dr Wendy Osborne, NCCC, Newcastle

Hodgkin lymphoma
Professor Graham Collins, Oxford University Hospitals

Register to enjoy the following sessions:

Immunotherapy

Mesenchymal stem cells
Professor Francesco Dazzi, London

Transplant for primary immunodeficiency in adults
Professor Emma Morris, London

Regulatory T cell (TREGs)
Professor Emma Morris, London

GVHD

New agents emerging in GVHD
Professor Ronjon Chakraverty, Oxford

ECP positioning based on RWD and ongoing clinical trails
Dr Francesca Kinsella, Birmingham

UK RATing study for risk adapted therapy for acute GVHD
Professor Adrian Bloor, Manchester

MDT with Difficult Cases

Dr Anjum Khan (Leeds), Dr Harpreet Kaur (Sheffield), Dr Francesca Kinsella (Birmingham)

Question Time

Dr Arun Alfred (Rotherham), Dr Anjum Khan (Leeds), Dr Harpreet Kaur (Sheffield), Dr Francesca Kinsella (Birmingham)

Registration is free of charge for HCPs working within the NHS

Supported by Mallinckrodt

Overview of WM and 1st line treatments
Dr Shirley D’Sa, UCLH

Latest BSH guidelines on WM – best practice
Dr Dima El-Sharkawi, Royal Marsden

A WM patient discussing their experience

• Patient experience of being diagnosed with WM: Bob Perry, Patient Support Manager WMUK
• Nursing challenges of managing a rare disease: Kerian McDonald and Beccy Veall, Leeds Teaching Hospitals

The holistic approach to management of WM as a multidisciplinary team
Aviva Cerner and Emma Rowles Clinical Nurse Specialists at UCLH

Peripheral neuropathy – cases
Guest Speaker: Dr Aisling Carr, Neurologist, Queen Square Hospital, London

What are the different treatment options 2nd line and beyond in relapse WM
– Regional variations & Clinical trials – what’s available
Dr Jaimal Kothari, Oxford University Hospitals

Supporting the whole family and practical support

• WMUK support line roll out : Alison McKinney, WMUK
• Support Networks: Bob Perry, Patient Support Manager, WMUK

Managing toxicities

• Lucy Whiteman, Royal Marsden and Charlotte Bloodworth, Cardiff
• Nurse Panel: Aviva Cerner, UCLH and Emma Rowles, UCLH

Supported by BeiGene